{"disease":{"id":"tsh-suppression-in-thyrotropin-dependent-well-differentiated-thyroid-cancer-adjunct-to-surgery","name":"TSH suppression in thyrotropin-dependent well-differentiated thyroid cancer - adjunct to surgery","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"levoxyl","indication_name":"TSH suppression in thyrotropin-dependent well-differentiated thyroid cancer - adjunct to surgery","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Levoxyl","generic_name":"Levothyroxine Sodium","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Thyroid receptor proteins attached to DNA","drug_class":"Thyroid hormone replacement","quality_score":10,"revenue":null,"mechanism":"Levothyroxine binds thyroid receptors in cell nuclei to activate gene transcription and protein synthesis."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[{"drug_id":"levoxyl","guideline_body":"FDA label","recommendation":"Levothyroxine sodium tablets are indicated as an adjunct to surgery in the management of thyrotropin-dependent well-differentiated thyroid cancer.","line_of_therapy":"adj","evidence_grade":"A","guideline_year":null},{"drug_id":"levoxyl","guideline_body":"FDA label","recommendation":"Levothyroxine sodium tablets are indicated as an adjunct to radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.","line_of_therapy":"adj","evidence_grade":"A","guideline_year":null}],"source":"Drug Landscape verified database"}